Voyager Therapeutics (Voyager Therapeutics) Debt-to-Equity : 0.09 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Voyager Therapeutics Debt-to-Equity?

Voyager Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.2 Mil. Voyager Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $17.1 Mil. Voyager Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $236.3 Mil. Voyager Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Voyager Therapeutics's Debt-to-Equity or its related term are showing as below:

VYGR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.34 Max: 0.47
Current: 0.09

During the past 11 years, the highest Debt-to-Equity Ratio of Voyager Therapeutics was 0.47. The lowest was 0.09. And the median was 0.34.

VYGR's Debt-to-Equity is ranked better than
61.4% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs VYGR: 0.09

Voyager Therapeutics Debt-to-Equity Historical Data

The historical data trend for Voyager Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics Debt-to-Equity Chart

Voyager Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.34

0.31

0.47

0.39

0.09

Voyager Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.39	0.10	0.11	0.12	0.09

Competitive Comparison of Voyager Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Voyager Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyager Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Debt-to-Equity falls into.

Voyager Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Voyager Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.2	+	17.093)	/	236.32
	=	0.09

Voyager Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.2	+	17.093)	/	236.32
	=	0.09

Voyager Therapeutics (NAS:VYGR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Voyager Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyager Therapeutics (Voyager Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (NAS:VYGR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

VT6:Germany VT6:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Executives

Todd Alfred Carter	officer: Chief Scientific Officer	C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET, CAMBRIDGE MA 02139
Robin Swartz	officer: Chief Operating Officer	C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Peter P. Pfreundschuh	officer: Chief Financial Officer	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sandell Jacquelyn Fahey	officer: Chief Legal Officer	C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET, CAMBRIDGE MA 02139
George A Scangos	director	C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Alfred Sandrock	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Robert W. Hesslein	officer: Senior VP & General Counsel	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Jude Onyia	director	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Neurocrine Biosciences Inc	10 percent owner	12780 EL CAMINO REAL, SAN DIEGO CA 92130
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Grace Colon	director	C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Glenn Pierce	director
Michael J Higgins	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140